Related IBB Turing Rejects $100 Million Offer For Daraprim Rich Ross Is Bullish On The NASDAQ Biotech ETF The Vetr community has downgraded $IBB to 3-Stars (Vetr)
Related XLV With House Vote, Trump And GOP Cheer As Obamacare Officially Begins Roll-Back Process Assessing The Odds Of An ACA Repeal And Replace....More>>>
Its time for the final push.
With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.
This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder....More>>>
This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests Jay Silverman, editor The Medical Technology Stock Letter.
Incyte (INCY) is poised for a strong performance in 2017 that will be driven by three major catalysts.
The first is that the firm’s drug Jakafi will continue to be a compelling....More>>>
Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $4.5 billion; its shares were traded at around $120.62 with a P/E ratio of 62.16 and P/S ratio of 8.35.....More>>>
Spark Therapeutics (NASDAQ: ONCE) is a primary gene therapy company to address patients suffering from inherited retinal disease (IRD), hemophilia and neurodegenerative diseases. The company presented the cumulative 1-year follow-up Phase 1/2 data of SPK-9001 infusion for the treatment of hemophilia B and preliminary on SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A at the American....More>>>
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of “3 Things In Biotech” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Shire enters the home stretch with its newer formulation of asparaginase
The stock market finished mixed on Tuesday, and although the Dow Jones Industrials still finished with a loss of more than 100 points, other major market benchmarks finished very close to the unchanged level on the day. Geopolitical pressure continued to hurt investor sentiment, and some bad news on the earnings front also cast a pall on trading during the regular session. Yet some stocks managed....More>>>
Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.
The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>
On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:
Large-Cap Biotechs Strength in Gilead and Amgen. We think....More>>>
The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.
The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>